EGFR and carcinoma: In a subset of patients, acquisition of resistance to EGFR inhibitors is associated with the phenomenon of epithelial-mesenchymal transition (EMT) [16–18], a plastic phenotypic conversion that allows carcinoma cells to acquire features typically associated with the mesenchymal phenotype [19, 20], including the ability to disseminate and to resist cell death [21, 22].